Twenty-first century oncology has also been found to have failed to take sufficient steps to reduce risks to a reasonable and acceptable level to satisfy 45 C.F.R. § 164.306 (A). United Therapeutics Corporation agreed to pay $210 million and reached a company integrity agreement to resolve allegations of bribe payments. United produces and distributes several medications to treat pulmonary arterial hypertension. The transaction resolved allegations that United violated the False Claims Act from 2010 to 2014 by paying bribes to Medicare patients by donating to the Caring Voice Coalition (CVC). CVC, meanwhile, reportedly used the donations to pay extra for patients, to entice patients to use United`s drugs. In addition to the civil transaction, 21st Century Oncology has entered into a new five-year investment agreement with the Office of Inspector General of the Department of Health and Human Services (HHS-OIG) that requires 21st Century Oncology to implement sweeping internal compliance reforms, including the recruitment of independent regulatory bodies to conduct annual claims audits and agreements. The Stark Law charges were originally made in a complaint filed by Matthew Moore, former acting vice president of financial planning for 21st Century Oncology, pursuant to Qui Tam`s provisions of the False Claims Act. Under the law, private parties can take legal action on behalf of the government and participate in a possible recovery. Mr. Moore receives $2,000,000 as his share in the recovery related to the Stark Law allegations. The transaction announced today decides on a disclosed behavior by the company with respect to government payments under the Medicare Electronic Health Records (EHR) Incentive Program. .